تحميل
HKSEHealthcareBiotechnology
أحدث البيانات المتاحة
28.60 HK$
+0.44 HK$ · +1.56%
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
أحدث البيانات المتاحة
28.60 HK$
+0.44 HK$ · +1.56%
تستخدم الأوقات اليومية المنطقة الزمنية HKT. قد تتأخر بيانات السوق.
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
نطاق اليوم
السعر الحالي 28.60 HK$
نطاق 52 أسبوعًا
السعر الحالي 28.60 HK$
تستخدم الأوقات اليومية المنطقة الزمنية HKT. قد تتأخر بيانات السوق.
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
نطاق اليوم
السعر الحالي 28.60 HK$
نطاق 52 أسبوعًا
السعر الحالي 28.60 HK$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
2359.HK
WuXi AppTec Co., Ltd.
208 HK$
-0.48%
1276.HK
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
48.00 HK$
-0.91%
6160.HK
BeOne Medicines AG
209.6 HK$
-1.60%
2269.HK
WuXi Biologics (Cayman) Inc.
53.85 HK$
-0.46%
3692.HK
Hansoh Pharmaceutical Group Company Limited
31.54 HK$
-1.99%
1801.HK
Innovent Biologics, Inc.
92.65 HK$
+0.05%
صناديق متداولة تفصح عن تعرضها لهذا السهم.
iShares Core MSCI Emerging Markets ETFIEMG3.81 مليون0.00%160.25 مليار USD0.09%81.40 US$+1.12%
iShares Genomics Immunology and Healthcare ETFIDNA1.95 مليون0.61%319.88 مليون USD0.47%42.17 US$+4.33%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX246.14 ألف0.04%664.9 مليون USD0.65%71.64 US$+1.00%
iShares MSCI China Small-Cap ETFECNS161.46 ألف0.26%62.09 مليون USD0.59%27.45 US$+1.72%
iShares Core MSCI Total International Stock ETFIXUS84.68 ألف0.00%58.62 مليار USD0.07%94.99 US$+0.90%
iShares MSCI Emerging Markets Small-Cap ETFEEMS75.35 ألف0.02%390.02 مليون USD0.72%76.085 US$+0.76%
State Street SPDR Portfolio MSCI Global Stock Market ETFSPGM66.03 ألف0.00%1.8 مليار USD0.09%87.44 US$+0.55%
State Street SPDR S&P China ETFGXC34.45 ألف0.01%446.48 مليون USD0.59%86.47 US$+1.87%iShares Core MSCI Emerging Markets ETFIEMGiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR S&P Emerging Markets Small Cap ETFEWXiShares MSCI China Small-Cap ETFECNSiShares Core MSCI Total International Stock ETFIXUSiShares MSCI Emerging Markets Small-Cap ETFEEMSState Street SPDR Portfolio MSCI Global Stock Market ETFSPGMState Street SPDR S&P China ETFGXCالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.